Monica E. Kleinman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Monica E. Kleinman has a total of 146 co-authors. Here are the top co-authors by number of shared publications:
- Leslie B. Gordon
Department of Anesthesia, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115, USA
5 shared publications - Vinay M. Nadkarni
Division of Critical Care Medicine, Department of Anesthesiology and Critical Care Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
4 shared publications - Allan de Caen
Division of Pediatric Critical Care, University of Alberta, Edmonton, Canada
3 shared publications - Dianne L. Atkins
University of Iowa
3 shared publications - Flemming Javier Olsen
Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte, Hellerup, Denmark
3 shared publications - Javier J. Lasa
Divisions of Cardiology and Critical Care Medicine, Children’s Health, UT Southwestern Medical Center, Dallas, TX
3 shared publications
Latest Publications
- 19 November 2025
- Published by Elsevier in Resuscitation
- Vol. 217, 110900
A comparison of adult basic life support recommendations in the latest guidelines
- 19 November 2025
- Published by Elsevier in Resuscitation
- Vol. 217, 110900
A comparison of adult basic life support recommendations in the latest guidelines
- Open Access
- 26 May 2025
- Published by Elsevier in Resuscitation Plus
- Vol. 24, 100991
Energy doses for paediatric defibrillation in cardiac arrest: systematic review and meta-analysis
- 26 May 2025
- Published by Elsevier in Resuscitation Plus
- Vol. 24, 100991
Open AccessEnergy doses for paediatric defibrillation in cardiac arrest: systematic review and meta-analysis
- 1 February 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 18 (2) , e017544
Longitudinal Changes in Myocardial Deformation in Hutchinson-Gilford Progeria Syndrome
- 1 February 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 18 (2) , e017544
Longitudinal Changes in Myocardial Deformation in Hutchinson-Gilford Progeria Syndrome
- 7 May 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 149 (19) , 1493-1500
Association Between Chest Compression Pause Duration and Survival After Pediatric In-Hospital Cardiac Arrest
BACKGROUND: The association between chest compression (CC) pause duration and pediatric in-hospital cardiac arrest survival outcomes is unknown. The American Heart Association has recommended minimizing pauses in CC in children to 10 seconds or >20 seconds and number of pauses >10 seconds and >20 seconds per 2 minutes. RESULTS: We identified 562 index in-hospital cardiac arrests (median [Q1, Q3] age 2.9 years [0.6, 10.0], 43% female, 13% shockable rhythm). Median length of the longest CC pause for each event was 29.8 seconds (11.5, 63.1). After adjustment for confounders, each 5-second increment in the longest CC pause duration was associated with a 3% lower relative risk of survival with favorable neurological outcome (adjusted risk ratio, 0.97 [95% CI, 0.95–0.99]; P =0.02). Longest CC pause duration was also associated with survival to hospital discharge (adjusted risk ratio, 0.98 [95% CI, 0.96–0.99]; P =0.01) and return of spontaneous circulation (adjusted risk ratio, 0.93 [95% CI, 0.91–0.94]; P 10 seconds or >20 seconds and number of CC pauses >10 seconds and >20 seconds were each significantly associated with adjusted risk ratio of return of spontaneous circulation, but not survival or neurological outcomes. CONCLUSIONS: Each 5-second increment in longest CC pause duration during pediatric in-hospital cardiac arrest was associated with lower chance of survival with favorable neurological outcome, survival to hospital discharge, and return of spontaneous circulation. Any CC pause >10 seconds or >20 seconds and number of pauses >10 seconds and >20 seconds were significantly associated with lower adjusted probability of return of spontaneous circulation, but not survival or neurological outcomes.
- 7 May 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 149 (19) , 1493-1500
Association Between Chest Compression Pause Duration and Survival After Pediatric In-Hospital Cardiac Arrest
BACKGROUND: The association between chest compression (CC) pause duration and pediatric in-hospital cardiac arrest survival outcomes is unknown. The American Heart Association has recommended minimizing pauses in CC in children to 10 seconds or >20 seconds and number of pauses >10 seconds and >20 seconds per 2 minutes. RESULTS: We identified 562 index in-hospital cardiac arrests (median [Q1, Q3] age 2.9 years [0.6, 10.0], 43% female, 13% shockable rhythm). Median length of the longest CC pause for each event was 29.8 seconds (11.5, 63.1). After adjustment for confounders, each 5-second increment in the longest CC pause duration was associated with a 3% lower relative risk of survival with favorable neurological outcome (adjusted risk ratio, 0.97 [95% CI, 0.95–0.99]; P =0.02). Longest CC pause duration was also associated with survival to hospital discharge (adjusted risk ratio, 0.98 [95% CI, 0.96–0.99]; P =0.01) and return of spontaneous circulation (adjusted risk ratio, 0.93 [95% CI, 0.91–0.94]; P 10 seconds or >20 seconds and number of CC pauses >10 seconds and >20 seconds were each significantly associated with adjusted risk ratio of return of spontaneous circulation, but not survival or neurological outcomes. CONCLUSIONS: Each 5-second increment in longest CC pause duration during pediatric in-hospital cardiac arrest was associated with lower chance of survival with favorable neurological outcome, survival to hospital discharge, and return of spontaneous circulation. Any CC pause >10 seconds or >20 seconds and number of pauses >10 seconds and >20 seconds were significantly associated with lower adjusted probability of return of spontaneous circulation, but not survival or neurological outcomes.
- Open Access
- 6 February 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (3) , e031470
Abnormal Myocardial Deformation Despite Normal Ejection Fraction in Hutchinson‐Gilford Progeria Syndrome
- 6 February 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (3) , e031470
Open AccessAbnormal Myocardial Deformation Despite Normal Ejection Fraction in Hutchinson‐Gilford Progeria Syndrome
- 6 June 2023
- Published by Wolters Kluwer Health in Circulation
- Vol. 147 (23) , 1782-1784
Progression of Cardiac Abnormalities in Hutchinson-Gilford Progeria Syndrome: A Prospective Longitudinal Study
- 6 June 2023
- Published by Wolters Kluwer Health in Circulation
- Vol. 147 (23) , 1782-1784
Progression of Cardiac Abnormalities in Hutchinson-Gilford Progeria Syndrome: A Prospective Longitudinal Study
- Open Access
- 6 June 2023
- Published by Wolters Kluwer Health in Circulation
- Vol. 147 (23) , 1734-1744
Plasma Progerin in Patients With Hutchinson-Gilford Progeria Syndrome: Immunoassay Development and Clinical Evaluation
Background: Hutchinson-Gilford progeria syndrome (HGPS) is an ultrarare, fatal, premature aging disease caused by a toxic protein called progerin. Circulating progerin has not been previously detected, precluding research using readily available biological samples. This study aimed to develop a plasma progerin assay to evaluate progerin’s quantity, response to progerin-targeted therapy, and relationship to patient survival. Methods: Biological samples were collected by The Progeria Research Foundation Cell and Tissue Bank from a non-HGPS cohort cross-sectionally and a HGPS cohort longitudinally. HGPS donations occurred at baseline and intermittently while treated with farnesylation inhibitors lonafarnib±pravastatin and zoledronate, within 3 sequential open-label clinical trials at Boston Children’s Hospital totaling >10 years of treatment. An ultrasensitive single-molecule counting progerin immunoassay was developed with prespecified performance parameters. Intra- and interpatient group statistics were descriptive. The relationship between progerin and survival was assessed by using joint modeling with time-dependent slopes parameterization. Results: The assay’s dynamic detection range was 59 to 30 000 pg/mL ( R 2 =0.9987). There was no lamin A cross-reactivity. Mean plasma progerin in non-HGPS participants (n=69; 39 male, 30 female; age, 0.2–71.3 years) was 351±251 pg/mL, and in drug-naive participants with HGPS (n=74; 37 female, 37 male; age, 2.1–17.5 years) was 33 261±12 346 pg/mL, reflecting a 95-fold increase in affected children ( P P =0.99). Lonafarnib treatment resulted in an average per-visit progerin decrease from baseline of between 35% to 62% (all P P <0.0001; ie, 15 000 pg/mL decrease yields a 63.9% decreased risk of death). For any given decrease in progerin, life expectancy incrementally increased with longer treatment duration. Conclusions: A sensitive, quantitative immunoassay for progerin was developed and used to demonstrate high progerin levels in HGPS plasma that decreased with lonafarnib therapy. The extent of improved survival was associated with both the magnitude of progerin decrease and duration at lower levels. Thus, plasma progerin is a biomarker for HGPS whose reduction enables short- and long-term assessment of progerin-targeted treatment efficacy. Registration: URL: https://www.clinicaltrials.gov . Unique identifiers: NCT00879034 and NCT00916747.
- 6 June 2023
- Published by Wolters Kluwer Health in Circulation
- Vol. 147 (23) , 1734-1744
Open AccessPlasma Progerin in Patients With Hutchinson-Gilford Progeria Syndrome: Immunoassay Development and Clinical Evaluation
Background: Hutchinson-Gilford progeria syndrome (HGPS) is an ultrarare, fatal, premature aging disease caused by a toxic protein called progerin. Circulating progerin has not been previously detected, precluding research using readily available biological samples. This study aimed to develop a plasma progerin assay to evaluate progerin’s quantity, response to progerin-targeted therapy, and relationship to patient survival. Methods: Biological samples were collected by The Progeria Research Foundation Cell and Tissue Bank from a non-HGPS cohort cross-sectionally and a HGPS cohort longitudinally. HGPS donations occurred at baseline and intermittently while treated with farnesylation inhibitors lonafarnib±pravastatin and zoledronate, within 3 sequential open-label clinical trials at Boston Children’s Hospital totaling >10 years of treatment. An ultrasensitive single-molecule counting progerin immunoassay was developed with prespecified performance parameters. Intra- and interpatient group statistics were descriptive. The relationship between progerin and survival was assessed by using joint modeling with time-dependent slopes parameterization. Results: The assay’s dynamic detection range was 59 to 30 000 pg/mL ( R 2 =0.9987). There was no lamin A cross-reactivity. Mean plasma progerin in non-HGPS participants (n=69; 39 male, 30 female; age, 0.2–71.3 years) was 351±251 pg/mL, and in drug-naive participants with HGPS (n=74; 37 female, 37 male; age, 2.1–17.5 years) was 33 261±12 346 pg/mL, reflecting a 95-fold increase in affected children ( P P =0.99). Lonafarnib treatment resulted in an average per-visit progerin decrease from baseline of between 35% to 62% (all P P <0.0001; ie, 15 000 pg/mL decrease yields a 63.9% decreased risk of death). For any given decrease in progerin, life expectancy incrementally increased with longer treatment duration. Conclusions: A sensitive, quantitative immunoassay for progerin was developed and used to demonstrate high progerin levels in HGPS plasma that decreased with lonafarnib therapy. The extent of improved survival was associated with both the magnitude of progerin decrease and duration at lower levels. Thus, plasma progerin is a biomarker for HGPS whose reduction enables short- and long-term assessment of progerin-targeted treatment efficacy. Registration: URL: https://www.clinicaltrials.gov . Unique identifiers: NCT00879034 and NCT00916747.
- 26 May 2023
- Published by Springer Nature
- p. 553-579
Anesthetic Complications in the Neonate: Incidence, Prevention, and Management
- 26 May 2023
- Published by Springer Nature
- p. 553-579
Anesthetic Complications in the Neonate: Incidence, Prevention, and Management
- Open Access
- 27 March 2023
- Published by Elsevier in Resuscitation Plus
- Vol. 14, 100379
Calcium during cardiac arrest: A systematic review
- 27 March 2023
- Published by Elsevier in Resuscitation Plus
- Vol. 14, 100379
Open AccessCalcium during cardiac arrest: A systematic review
- Open Access
- 14 March 2022
- Published by Elsevier in Clinical Simulation in Nursing
- Vol. 76, 39-46
A Multimodal Approach to Training Coronavirus Disease (COVID‐19) Processes Across Four Intensive Care Units
- 14 March 2022
- Published by Elsevier in Clinical Simulation in Nursing
- Vol. 76, 39-46
Open AccessA Multimodal Approach to Training Coronavirus Disease (COVID‐19) Processes Across Four Intensive Care Units